Alterity's Stock Is Trading Higher As ATH434 Preserves Neurons, Motor Performance In Animal Model With Neurodegenerative Disorder

Alterity Therapeutics ATHE has announced the presentation of expanded animal data to support the commercialization of its lead compound ATH434 in development to treat Parkinsonian disorders.
Data were presented at the American Academy of Neurology virtual annual meeting.
The data from an animal model of Multiple System Atrophy (MSA) independently confirm and extend previous findings demonstrating that ATH434 reduces α-synuclein pathology, preserves neurons, and improves motor function.
MSA is a rare neurodegenerative disorder characterized by autonomic dysfunction, tremors, slow movement, muscle rigidity, and postural instability.
The new data indicate that ATH434 preserves neurons not only in the substantia nigra, a main area of pathology in Parkinson's disease but also in the striatum, a region of the brain that integrates information from the cortex and substantia nigra to achieve fine motor control.
The study also showed that ATH434 led to reductions in glial cell inclusions, comprised of aggregated α-synuclein, and levels of the toxic form of α-synuclein, both of which are pathological features of MSA.
Price Action: ATHE shares are up 22.4% at $1.53 in premarket trading on the last check Wednesday.